Triplet therapy does not outperform doublet treatment first line in metastatic pancreatic cancer
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.